TG Therapeutics: Why I'm Staying Long After The Q2 Selloff (NASDAQ:TGTX)

seekingalpha.com · 2026-08-03

TG Therapeutics, Inc. stays a Buy as BRIUMVI revenue jumps and 2026 guidance rises; subcutaneous Phase 3 is a catalyst. Click for this TGTX stock update.

TickrTrends take: TG Therapeutics operates in the Healthcare sector where valuation metrics can shift significantly following quarterly results and market reactions. Given TickrTrends' current assessment of TGTX as undervalued, investors focused on valuation should monitor whether the Q2 selloff represented a genuine deterioration in fundamentals or created a pricing opportunity relative to the company's actual financial position. The Healthcare sector's sensitivity to clinical developments and earnings surprises means that valuation assessments require ongoing review of both operational performance and market sentiment shifts.

Read the full story at seekingalpha.com →